| Quality assessment | No of patients | Effect | Quality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Docetaxel, ifosfamide | Control | Relative (95% CI) | Absolute | |
| Overall survival | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | N=22 | - | Median OS = 4 months | ⊕○○○ VERY LOW | |
| Progression-free survival | |||||||||||
| 0 | No evidence available | ||||||||||
| Overall tumour response (assessed with: WHO criteria) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 5/20 (25%) | - | - | - | ⊕○○○ VERY LOW |
| Neutropenic sepsis (assessed with: WHO criteria) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 1/22 (4.5%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Thrombocytopenia (assessed with: WHO criteria) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 1/22 (4.5%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Anaemia (assessed with: WHO criteria) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 0/22 (0%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Leucopenia (assessed with: WHO criteria) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 11/53 (20.8%)4 | - | - | - | ⊕○○○ VERY LOW |
| Treatment-related mortality | |||||||||||
| 0 | No evidence available | ||||||||||
| Health-related quality of life | |||||||||||
| 0 | No evidence available | ||||||||||
Neoadjuvant (n=2) and adjuvant (n=4) chemotherapy considered as first-line chemotherapy;
Small sample size / low number of events limit the precision of this outcome
Reported as per cycle
From: 5, Managing locally advanced or metastatic bladder cancer
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.